公开(公告)号：US20050119286A1

公开(公告)日：2005-06-02

申请号：US10179612

申请日：2002-06-24

申请人： Michael Otto ,  Junxing Shi ,  Chung Chu ,  Raymond Schinazi ,  Giuseppe Gumina ,  Youhoon Chong ,  Yongseok Choi

发明人： Michael Otto ,  Junxing Shi ,  Chung Chu ,  Raymond Schinazi ,  Giuseppe Gumina ,  Youhoon Chong ,  Yongseok Choi

IPC分类号： A01N43/04 ,  A61K31/52 ,  A61K31/522 ,  A61K31/675 ,  A61K31/70 ,  A61K31/7064 ,  A61K31/7068 ,  A61K31/7076 ,  A61K45/00 ,  A61P31/14 ,  A61P31/18 ,  A61P35/00 ,  C07H9/04 ,  C07H19/06 ,  C07H19/16

CPC分类号： A61K31/70 ,  A61K31/52 ,  A61K31/522 ,  A61K31/675 ,  C07H9/04 ,  C07H19/06

摘要： The present invention includes compounds and compositions of β-halonucleosides, as well as methods to treat HIV, HBV or abnormal cellular proliferation comprising administering said compounds or compositions.

摘要翻译： 本发明包括β-卤代核苷的化合物和组合物，以及治疗HIV，HBV或异常细胞增殖的方法，包括施用所述化合物或组合物。

公开(公告)号：US20050209196A1

公开(公告)日：2005-09-22

申请号：US10530088

申请日：2003-12-08

申请人： Chung Chu ,  Raymond Schinazi

发明人： Chung Chu ,  Raymond Schinazi

IPC分类号： A61K31/505 ,  A61K31/513 ,  A61K31/52 ,  A61K31/65 ,  A61K31/675 ,  A61K31/70 ,  A61K45/06

CPC分类号： A61K45/06 ,  A61K31/505 ,  A61K31/513 ,  A61K31/52 ,  A61K31/65 ,  A61K31/675 ,  A61K31/70 ,  A61K2300/00

摘要： The present invention relates to the use of a dioxolane thymine compound according to the chemical structure of Formula (I): where R1 is H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate or phosphodiester group, for use in the treatment of HIV infections which exhibit resistance to 3TC and/or AZT. Preferably, compounds according to the present invention are combined with at least one anti-HIV agent which inhibits HIV by a mechanism other than through the inhibition of thymidine kinase (TK). These agents include those selected from among nucleoside reverse transcriptase inhibitors (NRTI), non-nucloeoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, among others. These agents are generally selected from the group consisting of 3TC (Lamivudine), AZT (Zidovudine), (−)-FTC, ddI (Didanosine), ddC (zalcitabine), abacavir (ABC), tenofovir (PMPA), D-D4FC (Reverset), D4T (Stavudine), Racivir, L-D4FC, NVP (Nevirapine), DLV (Delavirdine), EFV (Efavirenz), SQVM (Saquinavir mesylate), RTV (Ritonavir), IDV (Indinavir), SQV (Saquinavir), NFV (Nelfinavir), APV (Amprenavir), LPV (Lopinavir), fuseon and mixtures thereof. The TK dependent agents, such as AZT and D4T, may be used in combination with one of the dioloxane thymine compounds according to the present invention, but the use of such agents may be less preferred. In preferred compositions according to the present invention, R1 is preferably H or a C2-C18 acyl group or a monophosphate group. Pharmaceutical compositions and methods of reducing the likelihood that a patient at risk for contract an HIV infection will contract the infection are other aspects of the present invention.

公开(公告)号：US20050261320A1

公开(公告)日：2005-11-24

申请号：US10646980

申请日：2003-08-22

申请人： Chung Chu ,  Yung-Chi Cheng

发明人： Chung Chu ,  Yung-Chi Cheng

IPC分类号： A61K31/506 ,  A61K20060101 ,  A61K31/505 ,  A61K31/513 ,  A61P35/00 ,  C07D20060101 ,  C07D405/04 ,  C07F20060101 ,  C07H17/00 ,  C07D45/04

CPC分类号： C07D405/04 ,  C07H17/00

摘要： (−)-(2S,4S)-1-(2-Hydroxymethyl-1,3-dioxolan-4-yl)cytosine (also referred to as (−)-OddC) or its derivative and its use to treat cancer in animals, including humans.

摘要翻译： （ - ） - （2S，4S）-1-（2-羟甲基-1,3-二氧戊环-4-基）胞嘧啶（也称为（ - ） - OddC）或其衍生物及其用于治疗动物癌症的用途 ，包括人类。

公开(公告)号：US20050192299A1

公开(公告)日：2005-09-01

申请号：US10656889

申请日：2003-09-04

申请人： Yung-Chi Cheng ,  Chung Chu ,  Hea Kim ,  Kirupathevy Shanmuganathan

发明人： Yung-Chi Cheng ,  Chung Chu ,  Hea Kim ,  Kirupathevy Shanmuganathan

IPC分类号： A61K31/513 ,  A61K31/7076 ,  A61K38/21 ,  C07H17/00

CPC分类号： C07H17/00 ,  A61K31/513 ,  A61K31/7076 ,  A61K38/212 ,  A61K2300/00

摘要： Anti-hepatitis B virus compounds (−)3′-thia-2′,3′-dideoxycytidine, (−)5-fluoro-3′-thia-2′,3′-dideoxycytidine, (±) β-dioxolane cytosine and (−)-L-B-dioxolane cytosine. A method of treating a patient suffering from hepatitis B virus or preventing hepatitis B virus infection comprising administering to the patient an effective amount of an active compound selected from the group consisting of (a) (−)3′-thia-2′,3′-dideoxycytidine, (b) (±)3′-thia-2′3′-dideoxycytidine, (c) (−)5-fluoro-3′-thia-2′,3′-dideoxcytidine; (d) (±) 5-fluoro-3′-thia-2′3′-dideoxycytidine, (e)(±) β-dioxolane-cytosine and (f) (−)-L-β-dioxolane cytosine, or a salt or an ester thereof, either alone or in admixture within a diluent.

摘要翻译： 抗乙型肝炎病毒化合物（ - ）3'-硫杂-2'，3'-双脱氧胞苷，（ - ）5-氟-3'-硫杂-2'，3'-双脱氧胞苷，（±）β-二氧戊环胞嘧啶和 （ - ） - LB-二氧戊环胞嘧啶。 一种治疗患有乙型肝炎病毒或预防乙型肝炎病毒感染的患者的方法，包括向患者施用有效量的选自（a）（ - ）3'-硫杂-2'，3 （b）（±）3'-thia-2'3'-双脱氧胞苷，（c）（ - ）5-氟-3'-硫杂-2'，3'-脱氧胞嘧啶; （d）（±）5-氟-3'-硫杂-2'3'-二脱氧胞苷，（e）（±）β-二氧戊环 - 胞嘧啶和（f）（ - ） - L-β-二氧戊环胞嘧啶，或 盐或其酯，单独或混合在稀释剂内。

公开(公告)号：US20080069090A1

公开(公告)日：2008-03-20

申请号：US11984490

申请日：2007-11-19

申请人： Rafi Rabipour ,  Chung Chu ,  Pierre Gendron ,  William Navarro ,  Paul Boudreaux

发明人： Rafi Rabipour ,  Chung Chu ,  Pierre Gendron ,  William Navarro ,  Paul Boudreaux

IPC分类号： H04L12/66

CPC分类号： H04L12/66 ,  H04L12/6418 ,  H04L69/08 ,  H04L69/24 ,  H04L2012/6486 ,  H04M3/08 ,  H04M7/0027 ,  H04W76/12

摘要： A data communication apparatus, comprising an interface for enabling communication with a remote entity via a network and a control entity in communication with said interface. The control entity is operative to establish a packet-switched connection with the remote entity through the network and to negotiate with the remote entity using in-band signaling entry into a codec-bypass mode of operation. In this way, a codec-bypass connection, which enhances speech quality, can be established over a packet network, which reduces bandwidth.

摘要翻译： 一种数据通信装置，包括用于经由网络和与所述接口通信的控制实体与远程实体进行通信的接口。 控制实体可操作以通过网络与远程实体建立分组交换连接，并使用带内信令进入编解码器旁路操作模式与远程实体进行协商。 以这种方式，可以通过分组网络建立增强语音质量的编解码器旁路连接，从而降低带宽。

公开(公告)号：US20070259843A1

公开(公告)日：2007-11-08

申请号：US11777825

申请日：2007-07-13

申请人： Dennis Marcus ,  Chung Chu

发明人： Dennis Marcus ,  Chung Chu

IPC分类号： A61K31/35 ,  A61K31/40 ,  A61K31/405 ,  A61K31/44 ,  A61K31/497 ,  A61K31/56

CPC分类号： A61K31/56 ,  A61K9/0019 ,  A61K31/015 ,  A61K31/07 ,  A61K31/12 ,  A61K31/35 ,  A61K31/40 ,  A61K31/405 ,  A61K31/44 ,  A61K31/497 ,  A61K47/54 ,  A61K47/551 ,  A61K47/555 ,  Y10S514/914

摘要： The present invention describes linking a therapeutic agent to a compound which is known to be naturally concentrated in a tissue affected by, or that is causing, a disease, to create a prodrug for treatment of the disease. Embodiments of the present invention include a new class of carotenoid-linked drugs to treat such blinding retinal disease such as age-related macular degeneration, retinoblastoma, and diabetic macular edema. For example, the present invention comprises a method for the treatment of a disorder of the eye comprising linking a therapeutic agent to a xanthophyll carotenoid to create a prodrug, and administering a therapeutically effective amount of the prodrug to an individual in need of treatment. Provided are prodrugs for treatment of retinoblastoma, cystoid macular edema (CME), exudative age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, or inflammatory disorders.

摘要翻译： 本发明描述了将治疗剂与已知天然浓缩在受疾病或正在引起疾病的组织中的化合物连接以产生用于治疗疾病的前体药物。 本发明的实施方案包括一类新的类胡萝卜素相关药物来治疗这种致盲性视网膜疾病如年龄相关性黄斑变性，视网膜母细胞瘤和糖尿病性黄斑水肿。 例如，本发明包括用于治疗眼病的方法，包括将治疗剂与叶黄素类胡萝卜素连接以产生前药，以及将治疗有效量的前药施用于需要治疗的个体。 提供用于治疗视网膜母细胞瘤，囊性黄斑水肿（CME），渗出性年龄相关性黄斑变性（AMD），糖尿病性视网膜病变，糖尿病性黄斑水肿或炎症性疾病的前药。

公开(公告)号：US20070104114A1

公开(公告)日：2007-05-10

申请号：US11589435

申请日：2006-10-30

申请人： Chung Chu ,  Rafi Rabipour

发明人： Chung Chu ,  Rafi Rabipour

IPC分类号： H04J1/16

CPC分类号： H04L41/00 ,  H04L41/12

摘要： In a communications network having plural nodes, a first node receives a capability list that has a predefined format and includes plural entries identifying corresponding data processing functions supported by one or more nodes along a communications path of a communications session involving the first node. The first node adds at least one additional entry into the capability list in response to determining that the first node supports a data processing function that is not identified in the capability list.

摘要翻译： 在具有多个节点的通信网络中，第一节点接收具有预定义格式的能力列表，并且包括标识沿着涉及第一节点的通信会话的通信路径的一个或多个节点支持的相应数据处理功能的多个条目。 响应于确定第一节点支持在能力列表中未识别的数据处理功能，第一节点将至少一个附加条目添加到能力列表中。